Carmine Valenza: Our contribution regarding ESR1m, endocrine-responsive metastatic breast cancer

Carmine Valenza, MPH Student at Harvard T.H. Chan School of Public Health, shared a post on X:

“Happy to share our last contribution regarding ESR1m, endocrine-responsive mBC.

Patient selection according to clinical and molecular features is the key in the post-CDK4/6i setting.

Thanks to all the coauthors!”

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? published in ScienceDirect.

Author: C. Valenza, D. Trapani, F.-C Bidard, J. Gligorov, J. Cortés, N. Turner, F. Dalenc, F. Penault-Llorca, G. Freyer, M. Arnedos, C. Villanueva, S. Loibl, B. Pistilli, G. Curiglicano.

Additional information
Source: Carmine Valenza/X